Oppenheimer Maintains Outperform on Humana, Raises Price Target to $475

Oppenheimer analyst Michael Wiederhorn has maintained an Outperform rating on Humana (NYSE: HUM) and increased the price target from $405 to $475. This adjustment reflects a positive outlook for the company's performance in the market.